Search clinical trials for: 68Ga-pentixafor

Total 536 results

Stanford University

Not yet recruiting

68-Ga-FAPI PET Imaging in Malignancy

Cancer

United States
The First Affiliated Hospital of Xiamen University

Completed

68Ga-FAPI-RGD PET/CT for Dual Integrin αvβ3 and FAP-targeted Imaging in Patients With Various Types of Cancer and Compared With 18F-FDG

Positron-Emission Tomography | Tumor, Solid

China
Central Hospital, Nancy, France
GIE NANCYCLOTEP; Advanced Nuclear Medicine Ingredients (ANMI)

Unknown

Comparison of PET With 68GA-PSMA-11 and 18F-Fluorocholine for Recurrence in Men With Prostate Cancer (TEPGALCHOL)

Prostate Cancer

France
Azienda Ospedaliero-Universitaria di Modena

Recruiting

Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed (PSMA-PROSTAPET)

Neoplasms | Urogenital Neoplasms | Disease Attributes | Prostate Cancer | Prostatic Neoplasm | Prostatic Disease

Italy
The First Affiliated Hospital of Xiamen University

Recruiting

Comparison of FDG and FAPI in Patients With Various Types of Cancer

Metastasis | Positron-Emission Tomography | Tumor, Solid

China
West Virginia University

Recruiting

A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients

Head and Neck Squamous Cell Carcinoma

United States
Medical University of Vienna
BSM Diagnostica GmbH Vienna; Siemens Healthcare GmbH

Completed

PET/MRI in Patients With Suspected Prostate Cancer

Prostate Cancer

Austria
National University Hospital, Singapore
Tan Tock Seng Hospital

Unknown

Evaluation of Somatostatin Receptor Imaging Using PET/MRI as a Novel Approach to Detecting Pathology in Pulmonary TB

Tuberculosis

Singapore
Memorial Sloan Kettering Cancer Center

No longer available

68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial

Neuroendocrine Tumors

United States
Peking Union Medical College Hospital

Recruiting

68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer

Tumor, Solid

China
Thomas Hope
Clovis Oncology, Inc.

Recruiting

Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286

Myocardial Fibrosis | Pulmonary Fibrosis | Liver Fibrosis

United States
The Methodist Hospital Research Institute

Completed

68 Ga-PSMA for High Risk Prostate Cancer

Prostate Cancer | High Risk

United States
Ajit H. Goenka, MD

Completed

68 Ga PSMA PET/MRI for Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Active, not recruiting

Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Invasive Breast Lobular Carcinoma | Metastatic Breast Lobular Carcinoma

United States
Karolinska University Hospital

Recruiting

PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI

Stomach Neoplasms | Pancreatic Neoplasms | Epithelial Ovarian Cancer | Bile Duct Neoplasms

Sweden
Sue O'Dorisio

Completed

Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors (GA-68)

Neuroendocrine Tumors | Medulloblastoma | Neuroblastoma | Carcinoid Tumors

United States
Andrei Iagaru

Completed

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage IV Prostate Adenocarcinoma

United States
Ruijin Hospital

Recruiting

Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer

Gastric Cancer

China
Radboud University Medical Center
Dutch Cancer Society

Recruiting

PSMA-PET Imaging Before and After ADT in Advanced SDC Patients (ADT-SCAN)

Salivary Gland Cancer | Salivary Duct Carcinoma

Netherlands
Assistance Publique - Hôpitaux de Paris

Terminated

PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents (MLAPOCHI)

Advanced Head and Neck Carcinoma | Advanced Non-small Cell Lung Carcinoma

France
Peking Union Medical College Hospital

Unknown

68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological Findings

Epithelial Ovarian Cancer

China
Jonsson Comprehensive Cancer Center
Janssen Scientific Affairs, LLC

Recruiting

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial (HEATWAVE)

Prostate Adenocarcinoma | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8

United States
The First Affiliated Hospital of Xiamen University

Recruiting

68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG

Positron-Emission Tomography | FAP | SSTR2

China
Medical University of Bialystok
Medical Research Agency, Poland

Recruiting

Multicenter Assessment of Clinical Utility PET / MR With the Use of the Radiotracer 68Ga-PSMA-11 in Therapy Planning Personalized in Patients With Prostate Cancer (PROSPETMR2021)

Prostate Cancer

Poland
Weill Medical College of Cornell University

Completed

PSMA Imaging of Localized Prostate Cancer

Prostate Cancer

United States
Peking Union Medical College Hospital

Unknown

18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease

Crohn Disease
Novartis Pharmaceuticals

Not yet recruiting

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Metastatic Neuroendocrine Prostate Cancer
Sanofi
Antaros Medical

Completed

A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

Sweden
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC; United States Department of Defense

Recruiting

Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
BAMF Health
Telix International Pty Ltd

Recruiting

Total Body PET-CT Imaging of Prostate Cancer Using Illuccix

Metastatic Castration-resistant Prostate Cancer

United States
Weill Medical College of Cornell University

Active, not recruiting

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Prostate Cancer

United States
Direction Centrale du Service de Santé des Armées

Completed

Contribution of L-Tyrosine to Human Decision Making in Stressful Situations (TYRO-STRESS)

Stress, Psychological

France
Astellas Pharma Inc

Completed

A Study to Assess the Safety, Pharmacological Effect and Plasma Concentration of ASP7991 After Single Oral Administration to Healthy Volunteers

Healthy | Pharmacokinetics of ASP7991

Japan
First Affiliated Hospital of Fujian Medical University

Recruiting

68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer

Prostate Cancer | Positron-Emission Tomography

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Unknown

Unfavorable MRI But Favorable 68Ga-PSMA PET/MRI for Primary Prostate Cancer Detection

Prostate Neoplasm
Xijing Hospital

Completed

68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT

Lung Cancer | Lung Tuberculosis
AstraZeneca

No longer available

Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer

Adenocarcinoma of the Prostate
Novartis Pharmaceuticals

Recruiting

A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With PSMA-positive Prostate Cancer With or Without Prior 177Lu-PSMA Radioligand Therapy.

Metastatic Castration-resistant Prostate Cancer (mCRPC)

France
British Columbia Cancer Agency

Recruiting

DOTATOC PET/CT for Imaging NET Patients

Pituitary Adenoma | Neuroendocrine Tumors | Medulloblastoma | Small-cell Lung Cancer | Neuroblastoma | Meningioma | Merkel Cell Carcinoma | Pheochromocytoma | Paraganglioma | Gastrinoma | Glucagonoma | Insulinoma | Vipoma | Carcinoid | Ganglioneuroma | Medullary Carcinoma

Canada
Stanford University
National Cancer Institute (NCI)

Completed

68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer

Prostate Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation

Recruiting

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

Diffuse Large B Cell Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center

Active, not recruiting

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

Prostate Cancer

United States
Medical University of Warsaw

Completed

Predictive Values of Preoperative [68Ga]Ga-PSMA-11 PET/CT in Patients With Suspected Brain Tumours of Glial Origin

Glioma, Malignant | Glioma Glioblastoma Multiforme

Poland
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Withdrawn

Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer

Prostate Cancer
Novartis Pharmaceuticals

Recruiting

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Spain, France
Novartis Pharmaceuticals
Alliance Foundation Trials, LLC.; RTOG Foundation, Inc.

Active, not recruiting

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition)

Prostatic Neoplasms

United States, China, Canada, Spain, United Kingdom, Belgium, Japan, Taiwan, Germany, Singapore, Austria, Netherlands, Korea, Republic of, France, Switzerland, Denmark, Sweden, Poland, Czechia
Weill Medical College of Cornell University

Terminated

177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC

Prostate Cancer

United States
Mayo Clinic

Completed

d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis

Cardiac Sarcoidosis

United States
University of Lausanne Hospitals
George Coukos, MD PhD, Head of oncology

Recruiting

68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis

Pathological Angiogenesis

Switzerland
UNC Lineberger Comprehensive Cancer Center

Withdrawn

PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer

Prostate Cancer

United States

Search clinical trials for: 68Ga-pentixafor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations